Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

The Lancet Oncology

Volumn 11, Issue 1, 2010, Pages 55-65

  Albain, Kathy S ^a   Barlow, William E ^b   Shak, Steven ^c   Hortobagyi, Gabriel N ^d   Livingston, Robert B ^e   Yeh, I Tien ^f   Ravdin, Peter ^f   Bugarini, Roberto ^c   Baehner, Frederick L ^c   Davidson, Nancy E ^g   Sledge, George W ^h   Winer, Eric P ⁱ   Hudis, Clifford ^j   Ingle, James N ^k   Perez, Edith A ^l   Pritchard, Kathleen I ^m   Shepherd, Lois ⁿ   Gralow, Julie R ^o   Yoshizawa, Carl ^c   Allred, D Craig ^p   Osborne, C Kent ^q   Hayes, Daniel F ^r   more..

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c Genomic Health Inc   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^g UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^h INDIANA UNIVERSITY MEDICAL CENTER   (United States)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k MAYO CLINIC   (United States)

^l MAYO CLINIC   (United States)

^m UNIVERSITY OF TORONTO   (Canada)

ⁿ QUEEN S UNIVERSITY   (Canada)

^o SEATTLE CANCER CARE ALLIANCE   (United States)

^p WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^q Cancer Center   (United States)

^r UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HIGH RISK PATIENT; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; SCORING SYSTEM; TUMOR GENE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FLUOROURACIL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC TESTING; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPHATIC METASTASIS; MIDDLE AGED; PATIENT SELECTION; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ESTROGEN; RECURRENCE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 73249140371     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70314-6     Document Type: Article

References (33)

1. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 (2004) 2817-2826
2. Habel L.A., Shak S., Jacobs M.K., et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 8 (2006) R25
3. Van de Vijver M.J., He Y.D., van't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 247 (2002) 1999-2009
4. Van't Veer L.J., Paik S., and Hayes D.F. Gene expression profiling of breast cancer: a new tumor marker. J Clin Oncol 23 (2005) 1631-1635
5. Paik S., Tang G., Shak S., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24 (2006) 3726-3734
6. Oratz R., Paul D., Cohn A.L., and Sedlacek S.M. Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. J Oncol Pract 3 (2007) 182-186
7. Kamal AH, Loprinzi CL, Reynolds C, et al. How well do standard prognostic criteria predict Oncotype Dx scores? 2007 ASCO Annual Meeting; Chicago, IL, USA; June 1-5, 2007. Abstract 76.
8. Lo SS, Mumby PB, Rychlik K, et al. Extended follow-up results from a prospective multi-center study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection, satisfaction and anxiety. J Clin Oncol (in press).
9. Harris L., Fritsche H., Mennel R., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25 (2007) 5287-5312
10. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
11. Albain K., Barlow W., O'Malley F., et al. Concurrent versus sequential chemohormonal therapy versus tamoxifen alone for postmenopausal, node-positive, ER and/or PgR-positive breast cancer: mature outcomes and new biologic correlates on phase III intergroup trial 0100 (S8814). Breast Cancer Res Treat 90 (2005) 95
12. Fisher B., Jeong J.-H., Bryant J., et al. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 364 (2004) 858-868
13. Castiglione-Gertsch M., Price K.N., Goldhirsch A., et al. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial of the International Breast Cancer Study Group (Trial IX). J Natl Cancer Inst 994 (2002) 1054-1065
14. Hayes D.F., Thor A.D., Dressler L.G., et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 257 (2007) 1496-1506
15. Berry D.A., Cirrincione C., Henderson I.C., et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295 (2006) 1658-1667
16. Albain K.S., Barlow W.E., Ravdin P.M., et al., for The Breast Cancer Intergroup of North America. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet (2009) 10.1016/S0140-6736(09)61523-3 published online Dec 10.
17. Bull J.M., Tormey D.C., Li S.H., et al. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 41 (1978) 1649-1657
18. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., Clark G.M., and for the Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumour marker prognostic studies (REMARK). Br J Cancer 93 (2005) 387-391
19. Allred D.C., Harvey J.M., Berardo M., and Clark G.M. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11 (1998) 155-168
20. Royston P., and Parmar M.K. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med 21 (2002) 2175-2197
21. Singletary S.E., Allred C., Ashley P., et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20 (2002) 3628-3636
22. Mook S., Schmidt M.K., Viale G., et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat (2008) 10.1007/s10549-008-0130-2 published online July 27.
23. Sotiriou C., and Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 360 (2009) 790-800
24. Albain KS, Paik S, van't Veer L. Prediction of adjuvant chemotherapy benefit in endocrine-responsive early breast cancer using multigene assays. Breast (in press).
25. National Comprehensive Cancer Network. NCCN practice guidelines in oncology. Invasive breast cancer v.2.2008. http://www.nccn.org (accessed Oct 15, 2009).
26. Goldhirsch A., Wood W.C., Gelber R.D., et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18 (2007) 1133-1144
27. Dowsett M., Goldhirsch A., Hayes D.F., Senn H.J., Wood W., and Viale G. International web-based consultation on priorities for translational breast cancer research. Breast Cancer Res 9 (2007) R81
28. Goldhirsch A., Ingle J.N., Gelber R.D., et al. Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20 (2009) 1319-1329
29. Goldstein L.J., Gray R., Badve S., et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 26 (2008) 4063-4071
30. Knauer M., Straver M., Rutgers E., et al. The 70-gene MammaPrint signature is predictive for chemotherapy benefit in early breast cancer. Breast 18 suppl 1 (2009) S36 (abstract 73).
31. Gianni L., Zambetti M., Clark K., et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23 (2005) 7265-7277
32. Chapman J.-A., Meng D., Shepherd L., et al. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst 100 (2008) 252-260
33. Saphner T., Tormey D.C., and Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 13 (1996) 2738-2746